The segment recalls the 1997 recall of the diet drug Fen-Phen due to fatal heart valve complications. The hosts compare this history to the current Ozempic craze, noting that Pfizer's stock dropped after its own weight-loss pill failed clinical trials. They suggest that American pharmaceutical giants may eventually target Novo Nordisk's market dominance by highlighting safety concerns.